ASGCT 2021 | Horizon scanning in anti-CD19 CAR T-cell therapy

Marco Alessandrini, PhD, Antion Biosciences SA, Geneva, Switzerland, provides an overview of the advances seen so far in anti-CD19 chimeric antigen receptor (CAR) T-cell therapy research but highlights that there are still improvements to be made in terms of safety, efficacy and feasibility of these therapies. Future research should focus on improving treatment-related cytokine release syndrome (CRS) and central nervous system (CNS) conditions, improving treatment efficacy relative to standard of care and improving the accessibility of anti-CD19 CAR T-cell therapy in less sophisticated healthcare environments. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.